Results 171 to 180 of about 3,092 (212)

Report of the Ninth Asian National Control Laboratory Network meeting in 2024, with a focus on regional harmonization of regulatory systems to prepare for cross-border transfer of plasma.

Biologicals
Choi CW, Choi Y, Maryuningsih YS, Shin JH, Chantarasomchin P, Mizukami T, Ng SW, Thi DL, Ramondrana D, Dimapilis GN, Sohn KH, Roh HS, Koh HJ, Lee W, Kim YH.   +14 more
europepmc   +1 more source

Antitoxin therapy for botulinum intoxication

Reviews in Medical Microbiology, 2001
Botulinum toxin is the most toxic substance known to mankind. It is involved in infant botulism, classical food-borne botulism, wound botulism, and is a threat in biological warfare or bioterrorism.
Jane L Holley, Tim Brooks, Carl Nicholas Mayers   +2 more
openaire   +3 more sources

A review of WHO International Standards for botulinum antitoxins

Biologicals, 2006
Clostridium botulinum produces the most potent known toxins, with seven distinct serotypes currently defined (A-G). These toxins can cause a life threatening systemic toxicity whether through natural causes such as food poisoning, infant botulism, wound botulism, or through use as bio-terror agents (e.g. inhalational botulism). It was realised early on
Michael J. Corbel, Dorothea Sesardic, R.G.A. Jones   +2 more
openaire   +3 more sources

Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin

Toxicon, 2001
The neutralization of botulinum toxin serotype A with polyclonal equine antitoxin was studied in isolated mouse hemidiaphragms and compared to the same action in live mice. The biological activity of the toxin in the isolated muscle could be markedly reduced with excess antitoxin, estimated as 3:1 molar ratios of IgG Ab:toxin or better.
Robert E. Sheridan, Theresa J. Smith, Peter Amersdorfer, James D. Marks, Sharad S. Deshpande   +4 more
openaire   +4 more sources

Evaluation of botulinum antitoxin, supportive therapy, and artificial respiration in monkeys with experimental botulism

Clinical Pharmacology & Therapeutics, 1968
A diagnosis for botulism in man probably would not be made until after signs and symptoms developed. In this study the critical time for initiation of treatment was emphasized. Rhesus monkeys were given 2.5 to 5 LD50 of botulinum toxin, type A, intravenously. As soon as toxic signs were observed, therapy was initiated.
James W. Crook, Michael J. House, Fred W. Oberst, Paul Cresthull   +3 more
openaire   +4 more sources

Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F

Clinical Immunology, 2010
To produce a vaccine suitable for human use, a recombinant non His-tagged isoform of the Hc domain of botulinum neurotoxin serotype F (rFHc) was expressed in Escherichia coli and purified by sequential chromatography. The rFHc was evaluated as a subunit vaccine candidate in mouse model of botulism.
Shuang Wang, Zhi-Wei Sun, Yao Ma, Wen-Bing Wang, Pei-Tang Huang, Wei-Yuan Yu, Heng-Qi Zhu, Rui-Lin Wang, Xiao-Wei Zhou, Yun Du, Yun-Zhou Yu, Shu-Ming Zhang   +11 more
openaire   +4 more sources